| Rank |
Clinical Trial |
PubWeight™‹?› |
|
301
|
Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer
|
34.31
|
|
302
|
Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma (COMPARZ)
|
34.22
|
|
303
|
Protein Supplements to Treat High Blood Pressure
|
34.13
|
|
304
|
Efficacy of Pioglitazone on Macrovascular Outcome in Patients With Type 2 Diabetes (PROactive)
|
34.07
|
|
305
|
Interventional Management of Stroke (IMS) III Trial (IMSIII)
|
33.92
|
|
306
|
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
|
33.88
|
|
307
|
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
|
33.86
|
|
308
|
GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma
|
33.82
|
|
309
|
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
|
33.80
|
|
310
|
A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (BLISS-76)
|
33.71
|
|
311
|
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer (BOLERO-1)
|
33.60
|
|
312
|
The Hypertension in the Very Elderly Trial (HYVET)
|
33.58
|
|
313
|
Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients
|
33.58
|
|
314
|
Genetic Registry for Rheumatoid Arthritis (NARAC)
|
33.58
|
|
315
|
RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib (RECORD-1)
|
33.53
|
|
316
|
Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma
|
33.48
|
|
317
|
REVEAL Registry™: Registry to Evaluate Early And Long-term PAH Disease Management
|
33.43
|
|
318
|
A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)
|
33.41
|
|
319
|
An Open-Label, Multicenter, Phase 1/2 Study of E7438 (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B-cell Lymphomas
|
33.32
|
|
320
|
Temozolomide (TMZ) and Radiation Therapy (RT) With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (GBM)
|
33.28
|
|
321
|
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
|
33.28
|
|
322
|
Hypertension in Blacks of West African Origin
|
33.27
|
|
323
|
Botswana TDF/FTC Oral HIV Prophylaxis Trial (TDF2)
|
33.26
|
|
324
|
Silent Cerebral Infarct Transfusion Multi-Center Clinical Trial (SIT)
|
33.24
|
|
325
|
A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib (REACH)
|
33.14
|
|
326
|
Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors (TRX518-001)
|
33.09
|
|
327
|
Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM) (STORM)
|
33.04
|
|
328
|
CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL (CRETI-NH)
|
32.95
|
|
329
|
Hydroxychloroquine, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
|
32.87
|
|
330
|
Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)
|
32.85
|
|
331
|
Renal Denervation in Patients With Uncontrolled Hypertension (SYMPLICITY HTN-3)
|
32.76
|
|
332
|
Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia
|
32.70
|
|
333
|
CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies
|
32.69
|
|
334
|
Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial)
|
32.64
|
|
335
|
AZD9291 First Time In Patients Ascending Dose Study (AURA)
|
32.52
|
|
336
|
A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations
|
32.51
|
|
337
|
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
|
32.45
|
|
338
|
A Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab and the Combination Nivolumab Plus Ipilimumab in Patients With Advanced Liver Cancer (CheckMate040)
|
32.38
|
|
339
|
Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
|
32.34
|
|
340
|
Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer
|
32.31
|
|
341
|
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
|
32.27
|
|
342
|
Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial
|
32.21
|
|
343
|
Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma
|
32.20
|
|
344
|
Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer (VENICE)
|
32.07
|
|
345
|
Spine Patient Outcomes Research Trial (SPORT): Spinal Stenosis
|
32.04
|
|
346
|
National Growth and Health Study (NGHS)
|
31.95
|
|
347
|
Cryptococcal Optimal ART Timing Trial (COAT)
|
31.94
|
|
348
|
Dose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector For Gene Transfer in Hemophilia B
|
31.91
|
|
349
|
Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients
|
31.91
|
|
350
|
Rt-PA in the Treatment of Acute Ischemic Stroke
|
31.89
|
|
351
|
Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation (EngageAFTIMI48)
|
31.87
|
|
352
|
Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma
|
31.77
|
|
353
|
Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma (ARCC)
|
31.76
|
|
354
|
STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia
|
31.70
|
|
355
|
LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib
|
31.69
|
|
356
|
A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)
|
31.67
|
|
357
|
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
|
31.61
|
|
358
|
Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
|
31.59
|
|
359
|
Worcester Heart Attack Community Surveillance Study
|
31.58
|
|
360
|
A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
|
31.52
|
|
361
|
Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.
|
31.48
|
|
362
|
Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer
|
31.46
|
|
363
|
PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy
|
31.43
|
|
364
|
The Dual Antiplatelet Therapy Study (DAPT Study)
|
31.42
|
|
365
|
Bypass Angioplasty Revascularization Investigation (BARI)
|
31.40
|
|
366
|
Lymph Node Removal in Treating Women Who Have Stage I or Stage IIA Breast Cancer
|
31.30
|
|
367
|
Comparison of Two Types of Shunts in Infants With Single Ventricle Defect Undergoing Staged Reconstruction--Pediatric Heart Network
|
31.22
|
|
368
|
Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas
|
31.16
|
|
369
|
Ixabepilone and Hydroxychloroquine in Treating Patients With Metastatic Breast Cancer
|
31.15
|
|
370
|
Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA)
|
31.11
|
|
371
|
Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
|
31.01
|
|
372
|
Advanced Medical Therapy Versus Advanced Medical Therapy Plus Bariatric Surgery for the Resolution of Type 2 Diabetes
|
31.01
|
|
373
|
Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events (DECLARE-TIMI58)
|
31.00
|
|
374
|
Colorectal Cancer Screening in Average-risk Population: Immunochemical Fecal Occult Blood Testing Versus Colonoscopy
|
31.00
|
|
375
|
Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma
|
31.00
|
|
376
|
An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED)
|
30.99
|
|
377
|
Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone
|
30.97
|
|
378
|
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
|
30.91
|
|
379
|
Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens
|
30.91
|
|
380
|
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study
|
30.82
|
|
381
|
PREMIER: Lifestyle Interventions for Blood Pressure Control
|
30.78
|
|
382
|
Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis (FREEDOMS)
|
30.76
|
|
383
|
Pivotal Study of a Percutaneous Mitral Valve Repair System (EVERESTIIRCT)
|
30.66
|
|
384
|
Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy (STOP)
|
30.64
|
|
385
|
Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC) (ADAPT)
|
30.61
|
|
386
|
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
|
30.57
|
|
387
|
Study of Heart and Renal Protection (SHARP)
|
30.53
|
|
388
|
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer (COMET-2)
|
30.53
|
|
389
|
Pilot Investigation of Stem Cells in Stroke (PISCES)
|
30.39
|
|
390
|
A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
|
30.39
|
|
391
|
Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT (MULTIPRAT)
|
30.36
|
|
392
|
CALERIE (PBRC, Baton Rouge) - Comprehensive Assessment of Long-Term Effects of Reducing Intake of Energy
|
30.36
|
|
393
|
Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
|
30.30
|
|
394
|
Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults
|
30.27
|
|
395
|
Trial to Reduce Cardiovascular Events With Aranesp® Therapy (TREAT)
|
30.21
|
|
396
|
NORCCAP: Norwegian Colorectal Cancer Prevention Trial
|
30.18
|
|
397
|
Dietary Patterns and Risk of Cardiovascular Disease
|
30.14
|
|
398
|
INVEST: INternational VErapamil SR Trandolapril STudy
|
30.13
|
|
399
|
Hydroxychloroquine and Gefitinib to Treat Lung Cancer
|
30.13
|
|
400
|
Retrovirus Epidemiology Donor Study I (REDS I)
|
30.10
|